Droplet digital PCR for detection and quantification of circulating tumor DNA in plasma of head and neck cancer patients

BMC Cancer

Remco de Bree¹  Robert J. J. van Es²  Joost H. van Ginkel²  Manon M. H. Huibers³  Stefan M. Willems³ 

[1]Department of Head and Neck Surgical Oncology, UMC Utrecht Cancer Center, University Medical Center Utrecht

[2]Department of Oral and Maxillofacial Surgery, University Medical Center Utrecht

[3]Department of Pathology, University Medical Center Utrecht

关键词: Head and neck cancer;    Circulating tumor DNA;    Droplet digital PCR;    TP53 mutations;    Diagnostic biomarker;   

DOI  :  10.1186/s12885-017-3424-0

来源: DOAJ

【 摘 要 】

Abstract Background During posttreatment surveillance of head and neck cancer patients, imaging is insufficiently accurate for the early detection of relapsing disease. Free circulating tumor DNA (ctDNA) may serve as a novel biomarker for monitoring tumor burden during posttreatment surveillance of these patients. In this exploratory study, we investigated whether low level ctDNA in plasma of head and neck cancer patients can be detected using Droplet Digital PCR (ddPCR). Methods TP53 mutations were determined in surgically resected primary tumor samples from six patients with high stage (II-IV), moderate to poorly differentiated head and neck squamous cell carcinoma (HNSCC). Subsequently, mutation specific ddPCR assays were designed. Pretreatment plasma samples from these patients were examined on the presence of ctDNA by ddPCR using the mutation-specific assays. The ddPCR results were evaluated alongside clinicopathological data. Results In all cases, plasma samples were found positive for targeted TP53 mutations in varying degrees (absolute quantification of 2.2–422 mutational copies/ml plasma). Mutations were detected in wild-type TP53 background templates of 7667–156,667 copies/ml plasma, yielding fractional abundances of down to 0.01%. Conclusions Our results show that detection of tumor specific TP53 mutations in low level ctDNA from HNSCC patients using ddPCR is technically feasible and provide ground for future research on ctDNA quantification for the use of diagnostic biomarkers in the posttreatment surveillance of HNSCC patients.

【 授权许可】

Unknown